Infection Control Isn’t a Science Problem. It’s a Systems Problem.

We keep having the wrong conversation about healthcare-associated infections.

Every time HAI rates climb, the response is predictable: more training, more audits, more reminders to wash hands. We treat infection control as though it’s a knowledge gap — as if the nurses, environmental services workers, and infection preventionists on the front lines simply don’t know enough or care enough to get it right.

That framing is not only wrong. It’s actively harmful, because it lets the real problem off the hook.

Infection control failures aren’t a science problem. They aren’t a training problem. And they certainly aren’t a time problem. They are a systems problem — and the system we have built is, in many ways, working exactly as designed.

The People Doing the Work Are Undervalued

Let’s start there. Environmental health and safety professionals — the people responsible for keeping hospital environments clean and safe — are among the most underpaid and underrecognized workers in healthcare. They carry enormous responsibility for patient safety outcomes, yet their compensation and organizational standing rarely reflect that. When a CLABSI happens, no one points to the facility’s EHS staffing ratios or turnover rate. They should.

When the people doing this work aren’t supported, resourced, or recognized, the entire infection prevention infrastructure weakens from the foundation up. No amount of training fixes a staffing and compensation problem.

The Regulatory Pathway Is Broken for Innovation

Here’s a reality that doesn’t make it into enough conversations: there is technology available today that could meaningfully interrupt the chain of transmission. Novel antimicrobial platforms. Surface-active compounds. Chemistry that outperforms what’s currently on the market in ways that matter clinically.

And much of it is sitting in a regulatory waiting room.

Getting a new disinfectant registered with the EPA can take five years and upward of three million dollars. For a small company with genuinely differentiated technology, that timeline isn’t a hurdle — it’s a wall. The regulatory process was designed for a different era, and it hasn’t kept pace with the innovation it’s supposed to evaluate. The result is that better tools don’t reach the people who need them, while the products already on the market maintain their position by default.

Even EPA Registration Isn’t Enough

Let’s say a company does clear the EPA. They have the data. They have the registration. They’re ready to sell into hospitals.

Then they meet the GPO.

Group Purchasing Organizations control a significant share of what gets bought in healthcare facilities. Multi-year contracts with established brands create an almost impenetrable market structure for newer entrants — even when those entrants have a demonstrably better product. The economics of healthcare procurement weren’t designed to reward innovation. They were designed to reward volume and incumbency. The result is that hospital purchasing decisions are often made years in advance, by people who may never touch a mop or a disinfectant wipe, based on contracts that have little room for something new, even when “something new” could reduce patient harm.

Medical Device Manufacturers Share the Problem

And then there are the devices themselves. Medical device manufacturers have a well-documented pattern of publishing instructions for use that are, in practice, impossible to follow. Disinfection contact times that require surfaces to remain visibly wet for minutes. Cleaning protocols that assume materials and staffing levels that don’t exist in real-world clinical environments. Compatibility requirements that are neither validated nor practical.

When the IFU can’t be followed in the real world, it doesn’t get followed. Devices that should be cleaned and disinfected between patients aren’t, not because staff don’t care, but because the instructions were written for a compliance document, not a busy unit.

The System Is Working as Designed. That’s the Problem.

Look at the diagram. Regulatory agencies operating with very little cross-collaboration. Disinfectant suppliers navigating an EPA process that limits what reaches the market. GPOs controlling hospital access. Medical device manufacturers setting unrealistic standards. Supply chain networks moving materials through a system that wasn’t optimized for infection prevention outcomes.

Every piece of that system influences what happens at the point of care — and none of it is coordinated around reducing HAIs.

HAI rates are not rising because healthcare workers don’t know how to clean a surface. They are rising because the system surrounding that worker is misaligned, underfunded, and resistant to change at almost every point.

The solution isn’t another hand hygiene campaign. It’s redesigning the system. Fix the regulatory pathway so innovation can move. Fix the procurement model so better products can compete. Fix the IFU process so manufacturers are held to standards that are actually achievable. Fix the investment in EHS professionals so the people doing this work are treated like the patient safety professionals they are.

Fix the system. Fix the risk.